DZ Bank’s Acadia Pharmaceuticals ACAD Stock Holding History

DZ Bank’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-194,146	Closed	-$5.19M	–	1004
2025 Q4	$5.19M	Buy	194,146 +123,109	+173%	+$2.94M	﹤0.01%	503
2025 Q3	$1.52M	Buy	+71,037	New	+$1.68M	﹤0.01%	659
2024 Q1	–	Sell	-26,380	Closed	-$826K	–	1029
2023 Q4	$826K	Buy	26,380 +10,549	+67%	+$252K	﹤0.01%	687
2023 Q3	$330K	Buy	+15,831	New	+$430K	﹤0.01%	769
2018 Q2	–	Sell	-41,911	Closed	-$941K	–	849
2018 Q1	$941K	Buy	+41,911	New	+$1.16M	﹤0.01%	672

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

DZ Bank's ACAD Position: Q1 2026 in Review

DZ Bank sold out of Acadia Pharmaceuticals (ACAD) in Q1 2026, closing a stake of 194,146 shares — an estimated $5.19M sold.

DZ Bank first reported a position in ACAD in Q1 2018 and held it in 5 quarters. The position peaked at $5.19M in Q4 2025. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

DZ Bank reported no remaining Acadia Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
DZ Bank sold 194,146 Acadia Pharmaceuticals shares in Q1 2026, an estimated $5.19M.
DZ Bank first reported a position in Acadia Pharmaceuticals in Q1 2018 and held it in 5 quarters.
DZ Bank's Acadia Pharmaceuticals position peaked at $5.19M in Q4 2025.
340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on DZ Bank's 13F filing for Q1 2026, filed 15 May 2026.